A Phase 1/2 Study to Evaluate the Triplet Combination of NKTR-214 Plus Nivolumab and Axitinib and the Doublet Combination of Nivolumab and Axitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
The purpose of this study is to determine the safety of bempegaldesleukin combined with nivolumab and axitinib (Part 1), and then to evaluate the effectiveness of the nivolumab, bempeg, and axitinib triplet regimen in participants with previously untreated kidney cancer that has advanced or has spread (Part 2).
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society